The GSK AS01E-adjuvanted RSV preFusion protein 3 OA (adjuvanted RSVPreF3 OA) vaccine has shown efficacy in preventing RSV infection and RSV-associated lower respiratory tract disease (LRTD) in adults aged 60 y or more [20]. This evidence concerns the gene HSPB3 and lower respiratory tract disorder.